Utility estimation in chronic obstructive pulmonary disease: A preference for change?

PharmacoEconomics

Volumn 29, Issue 11, 2011, Pages 917-932

  Petrillo, Jennifer ^a   Van Nooten, Floortje ^b   Jones, Paul ^c   Rutten Van Mölken, Maureen ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Health status; Quality adjusted life years; Quality of life; Utility measurement.

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY QUESTIONNAIRE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISCRIMINANT VALIDITY; DISEASE EXACERBATION; DISEASE SEVERITY; ECONOMIC EVALUATION; EQ 5D QUESTIONNAIRE; EXACERBATIONS OF CHRONIC PULMONARY DISEASE TOOL; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HEALTH STATUS; HEALTH UTILITIES INDEX; HUMAN; MULTIATTRIBUTE UTILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF WELL BEING SCALE; SENSITIVITY ANALYSIS; SHORT FORM 36; ST GEORGE RESPIRATORY QUESTIONNAIRE; VALIDATION PROCESS;

COST-BENEFIT ANALYSIS; EVALUATION STUDIES AS TOPIC; HEALTH STATUS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 80054118462     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11589280-000000000-00000     Document Type: Article

References (94)

1. WHO. Chronic obstructive pulmonary disease (COPD). Fact sheet No. 315, February 2011 [online]. Available from URL: http://www.who.int/mediacentre/ factsheets/fs315/ en/index.html [Accessed 2011 Jul 4]
2. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006 Sep; 28 (3): 523-32 (Pubitemid 44794666)
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun; 23 (6): 932-46 (Pubitemid 38807371)
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. GOLD, 2009 [online]. Available from URL: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2= 1&intId=2003 [Accessed 2010 Sep 13]
5. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117 (5 Suppl. 2): 398-401S (Pubitemid 30314474)
6. Rodríuez-Roisin R. COPD exacerbations. 5: management. Thorax 2006 Jun; 61 (6): 535-44
7. Jones PW. Health status: what does it mean for payers and patients? Proc Am Thorac Soc 2006 May; 3 (3): 222-6 (Pubitemid 43668185)
8. Miravitlles M, Anzueto A, Legnani D, et al. Patient's perception of exacerbations of COPD: the PERCEIVE study. Respir Med 2007 Mar; 101 (3): 453-60 (Pubitemid 46196335)
9. Russell LB, Gold MR, Siegel JE, et al. The role of costeffectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 Oct 9; 276 (14): 1172-7 (Pubitemid 26329746)
10. Prieto L, Sacristan JA. What is the value of social values? The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol 2004 Apr 29; 4: 10
11. Feeny D. Commentary on Jack Dowie, Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions. Health Econ 2002 Jan; 11 (1): 13-6; discussion 21-2 (Pubitemid 34097616)
12. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 Jul; 33 (5): 337-43 (Pubitemid 32675374)
13. Ringbaek T, Brondum E, Martinez G, et al. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008 Nov; 102 (11): 1563-7
14. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991 Sep; 85 Suppl. B: 25-31; discussion 3-7
15. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145 (6): 1321-7
16. Hesselink AE, van der Windt DA, Penninx BW, et al. What predicts change in pulmonary function and quality of life in asthma or COPD? J Asthma 2006 Sep; 43 (7): 513-9 (Pubitemid 44567603)
17. Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. Eur Respir J 2009 May; 33 (5): 953-5
18. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997 Apr; 155 (4): 1283-9 (Pubitemid 27172772)
19. Verhage TL, Heijdra YF, Molema J, et al. Adequate patient characterization in COPD: reasons to go beyond GOLD classification. Open Respir Med J 2009; 3: 1-9
20. Wijnhoven HA, Kriegsman DM, Hesselink AE, et al. Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life. Chest 2001 Apr; 119 (4): 1034-42 (Pubitemid 32679427)
21. Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ 2010 Feb; 19 (2): 125-9
22. Pickard AS, Wilke C, Jung E, et al. Use of a preferencebased measure of health (EQ-5D) in COPD and asthma. Respir Med 2008 Apr; 102 (4): 519-36
23. Brown G, Austin J, McGowan I, et al. Is the EuroQol generic health status questionnaire sensitive to the impact of pulmonary rehabilitation in COPD? [abstract]. Am J Respir Crit Care Med 2009; 179: A3852
24. Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997 Oct; 52 (10): 879-87 (Pubitemid 27473930)
25. Hazell M, Frank T, Frank P. Health related quality of life in individuals with asthma related symptoms. Respir Med 2003 Nov; 97 (11): 1211-8 (Pubitemid 37337018)
26. Punekar YS, Rodriguez-Roisin R, Sculpher M, et al. Implications of chronic obstructive pulmonary disease (COPD) on patients' health status: a western view. Respir Med 2007 Mar; 101 (3): 661-9 (Pubitemid 46205904)
27. Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8 (2): 123-35 (Pubitemid 46742896)
28. Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56
29. Stå hl E, Lindberg A, Rönmark E, et al. The level of ealthrelated quality of life in patients with COPD and its dependence on age, gender and disease severity. Eur Respir J 2001; 18 Suppl. 33: S184
30. Stavem K. Association of willingness to pay with severity of chronic obstructive pulmonary disease, health status and other preference measures. Int J Tuberc Lung Dis 2002 Jun; 6 (6): 542-9 (Pubitemid 34601873)
31. StavemK.Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8 (1-2): 45-54 (Pubitemid 29362745)
32. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Medical Care 2005; 43 (7): 736-49 (Pubitemid 40993769)
33. Szende A, Leidy NK, Stahl E, et al. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res 2009 Mar; 18 (2): 267-72
34. Goossens L, Rutten-van Mölken M, Nivens C. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? ISPOR 11th Annual European Congress; 2008 Nov 8-11; Athens
35. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations: comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010; 8 (1): 39
36. O'Reilly JF,Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007 Jul; 61 (7): 1112-20 (Pubitemid 46934632)
37. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the Measure Your Medical Outcome Profile (MYMOP), Medical Outcomes Study 6-Item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000; 9 (5): 521-7 (Pubitemid 32009862)
38. Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999; 16 (5 Pt 1): 499-520 (Pubitemid 29530153)
39. Vardeva K, Spencer MD, Punekar Y. Development of preference-based EQ-5D utility values for the St George's Respiratory Questionnaire: Chronic Obstructive Pulmonary Disease (SGRQ-COPD). 10th Annual ISPOR European Congress; 2007 Oct 20-23; Dublin
40. Starkie H, Briggs A, Chambers M. Mapping the St George's Respiratory Questionnaire to utility values using the EQ5D. 30th Annual Meeting of the Society for Medical Decision Making; 2008 Oct 19-22; Philadelphia (PA)
41. Marra CA, Sullivan SD, Najafzadeh M, et al. Mapping the EQ-5D from the St. George's Respiratory Questionnaire in a clinical trial of COPD treatments: results from the OPTIMAL trial. 10th Annual ISPOR European Congress; 2007 Oct 20-23; Dublin
42. Meguro M, Jones PW. Item selection for COPD-specific utility instrument (abstract no. PCO2). Value Health 2004; 7 (6): 684
43. Meguro M, Jones PW. Elicitation of utility weights for a COPD specific preference measure [abstract]. Am J Resp Crit Care Med 2006; 3: A488
44. Petrillo J, Cairns J. Development of the EXACT-U: a preference- based measure to report COPD exacerbation utilities. Value Health 2011; 14 (4): 546-54
45. Rutten-van Mölken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: The case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009; 27 (6): 465-77
46. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004 Sep; 13 (9): 873-84 (Pubitemid 39264234)
47. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35 (11): 1095-108 (Pubitemid 127453463)
48. Feeny D, Furlong W, Boyle M, et al. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490-502
49. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988 Jun; 23 (2): 203-35
50. Kaplan RM, Ganiats TG, Sieber WJ, et al. The Quality of Well-Being scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998 Dec; 10 (6): 509-20 (Pubitemid 29037244)
51. Rutten-van Mölken M, Roos B, Van Noord JA. An empirical comparison of the St. George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999 Nov; 54 (11): 995-1003
52. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 503-20
53. National Institute for Health and Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: NICE, 2008
54. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008 Feb; 31 (2): 416-69
55. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004 Mar-Apr; 7 (2): 153-67 (Pubitemid 38420728)
56. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619-37 (Pubitemid 40994129)
57. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006 Oct; 130 (4): 1117-28
58. Rutten-van Mölken MRV, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (7): 630-4 (Pubitemid 44411632)
59. McBride A, Milne R. Hospital-based pulmonary rehabilitation programmes for patients with severe chronic obstructive pulmonary disease. Southampton: Wessex Institute for Health Research and Development, University of Southampton, 1999. DEC report No. 94
60. Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 Mar 1; 171 (5): 446-52 (Pubitemid 40444244)
61. Brooks R. The measurement and valuation of health status using EQ-5D: a European perspective. In: Brooks R, Rabin R, de Charro F, editors. Evidence from the Euro- Qol BIO MED Research Programme. Dordrecht: Kluwer Academic Publishers, 2003
62. Bharmal M, Thomas J. Comparing the EQ-5D and the SF- 6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006; 9 (4): 262-71 (Pubitemid 44126781)
63. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003 Jun; 41: 29-35s (Pubitemid 36648152)
64. Buss AS, da Silva LM. Comparative study of two quality of life questionnaires in patients with COPD. J Bras Pneumol 2009 Apr; 35 (4): 318-24
65. Briggs A, Glick H, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010; 35 (3): 532-9
66. Decramer M, Dekhuijzen PN, Troosters T, et al. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS trial Committee. Eur Respir J 2001 Mar; 17 (3): 329-36 (Pubitemid 32600597)
67. Guyatt GH, King DR, Feeny DH, et al. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999 Mar; 52 (3): 187-92 (Pubitemid 29148429)
68. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD: a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009; 4 (1): 203-23
69. Bourbeau J, Ford G, Zackon H, et al. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007 Nov; 30 (5): 907-13 (Pubitemid 351194794)
70. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002 Mar; 121 (3): 688-96 (Pubitemid 34251429)
71. Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 2008; 28 (1): 66-89
72. Petrillo J, Cairns J. Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Exp Rev Pharmacoeconomics Outcomes Res 2008; 8 (5): 453-61
73. Brazier J, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition-specific measure: the King's health questionnaire. Med Decis Making 2008; 28 (1): 113-26
74. McKenna SP, Ratcliffe J, Meads DM, et al. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes 2008; 6: 65
75. Koltowska-Haggstrom M, Jonsson B, Isacson D, et al. Using EQ-5D to derive general population-based utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA). Value Health 2007; 10 (1): 73-81 (Pubitemid 46164755)
76. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest 1998; 114 (4): 998-1007 (Pubitemid 28495893)
77. Brazier J, Dixon S. The use of condition specific outcome measures in economic appraisal. Health Econ 1995; 4 (4): 255-64
78. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD. Version 1.2. New York: American Thoracic Society, 2004 [online]. Available from URL: http://www.thoracic.org/go/copd [Accessed 2005 Sep 8]
79. Fan VS, Ramsey SD, Make BJ, et al. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD 2007 Mar; 4 (1): 29-39 (Pubitemid 46348290)
80. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010; 13 (8): 965-75
81. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183 (3): 323-9
82. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42 (9): 851-9 (Pubitemid 39456916)
83. McTaggart-Cowan HM, Marra CA, Yang Y, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Quality Life Res 2008; 17 (3): 453-62
84. Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006; 24 (11): 1069-78 (Pubitemid 44683364)
85. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008 Nov; 63 (11): 962-7
86. Petrillo J, Macker S, Davies E, et al. Development of a preference-based algorithm to report utilities for exacerbations of COPD from the EXACT. Value Health 2011; (14) 546-54
87. Petrillo J, Cairns J. Evaluation of COPD exacerbations using the EXACT-U. European Respiratory Society Annual Congress; 2010 Sep 18-22; Barcelona
88. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3 (9): iii-163
89. Mahler DA, Mackowiak JI. Evaluation of the shortform 36-Item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995 Jun; 107 (6): 1585-9
90. Burstrom K, JohannessonM, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006; 76 (3): 359-70 (Pubitemid 46137849)
91. Stiggelbout AM, de Vogel-Voogt E. Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 2008 Jan-Feb; 11 (1): 76-87 (Pubitemid 351160878)
92. US FDA. Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Rockville (MD):USDepartment ofHealth and Human Services, 2007 [online]. Available from URL: http://www.fda.gov/down loads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071575.pdf [Accessed 2010 Sep 21]
93. US FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville (MD): US Department of Health and Human Services, 2009 [online]. Available from URL: http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegula toryInformation/Guidances/UCM193282.pdf [Accessed 2010 Sep 21]
94. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009; 7: 27.